BioCryst Pharmaceuticals Inc

BCRXNASDAQ • USD
ThemeBiotech - Drug Development›Rare Disease Therapeutics
9.29 USD
↗ 0.19 (2.03%)AT CLOSE (11:59 AM EDT)
9.28
↘ 0.01 (0.06%)
POST MARKET (AS OF 07:23 PM EDT)
Post Market
AS OF 07:23 PM EDT
9.28
↘ 0.01 (0.06%)
🔴Market: CLOSED

BCRX is currently priced at $9.29. Our models show a "Neutral" technical signal alongside a "Sell" fundamental rating. Key drivers include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 1/9, exceptional Return on Equity (82.7%) and a bullish Golden Cross on the moving averages. On the valuation side, BCRX appears attractively valued relative to sector peers across key multiples.

Technical & fundamental data as of Jul 17, 2026.

Open?$8.99
High?$9.32
Low?$8.95
Prev. Close?$9.11
Volume?3.3M
Avg. Volume?5.7M
VWAP?$9.16
Rel. Volume?0.57x
Bid / Ask
Bid?$7.92 × 100
Ask?$10.83 × 100
Spread?$2.91
Midpoint?$9.38
Valuation & Ratios
Market Cap?2.3B
Shares Out?254.2M
Float?199.3M
Float %?94.6%
P/E Ratio?N/A
P/B Ratio?-4.18
EPS?-$1.80
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
Themes
Biotech - Drug Development›Rare Disease TherapeuticsBiotech - Drug Development›Infectious Disease & Vaccines
Employees
435
Market Cap
2.3B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.biocryst.com
Listed
1994-03-03
Address
4505 EMPEROR BOULEVARD
DURHAM, NC 27703
Phone: 919-859-1302
Technical OutlookNeutral
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
6
Z-Score?
0
Momentum?
77
Short Sent.?
21
Piotroski F-Score?1/9Weak
Altman Z-Score?-5.69Distress
Confidence?57%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?24.43%Squeeze Risk
Short Interest?48.7M
Days to Cover?6.0
Free Float199.3M
Avg Daily Volume8.1M
Settlement Date2026-06-30
Financial Health
Current Ratio?1.91Adequate
Quick Ratio?1.88Adequate
Cash Ratio?0.88Adequate
Debt/Equity?-1.53Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
93/100
P/E?
N/A▾
P/B?
S&P
97
-4.18CHEAP▾
P/S?
Peers
100
S&P
56
2.61CHEAP▾
P/FCF?
Peers
100
S&P
94
7.5CHEAP▾
EV/EBITDA?
S&P
97
-7.9CHEAP▾
EV/Sales?
Peers
100
S&P
55
3.37FAIR▾
Returns & Efficiency
ROE?
Peers
50
S&P
97
82.7%STRONG▾
ROA?
S&P
3
-98.5%WEAK▾
Cash Flow & Enterprise
FCF?$310.4M
Enterprise Value?$3.0B
Fundamentals ratios updated end of day
MarketsMoversWatchlist